Format

Send to

Choose Destination
Chembiochem. 2016 Jan;17(2):155-8. doi: 10.1002/cbic.201500591. Epub 2015 Dec 10.

A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2-Positive Breast Cancer Cells.

Author information

1
Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA.
2
Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT, 06511, USA.
3
Department of Chemistry, Colorado State University, Fort Collins, CO, 80523, USA. brian.mcnaughton@colostate.edu.
4
Department of Biochemistry and Molecular Biology, Colorado State University, Fort Collins, CT, 80523, USA. brian.mcnaughton@colostate.edu.

Abstract

We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl (anti-DNP) antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease-relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.

KEYWORDS:

HER2; activation immunotherapeutic; breast cancer; immunotherapy; nanobody

PMID:
26556305
PMCID:
PMC5199233
DOI:
10.1002/cbic.201500591
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center